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BACKGROUND AND PURPOSE
Inflammation plays a key role in atherosclerosis. The protective role of angiotensin 1–7 (Ang-(1–7)) in vascular pathologies sug-
gested the therapeutic use of lowMW, non-peptide Ang-(1–7) mimetics, such as AVE0991. The mechanisms underlying the vaso-
protective effects of AVE0991, a Mas receptor agonist, remain to be explored.
EXPERIMENTAL APPROACH
We investigated the effects of AVE0991 on the spontaneous atherosclerosis in apolipoprotein E (ApoE)/mice, in the context of
vascular inflammation and plaque stability.
KEY RESULTS
AVE0991 has significant anti-atherosclerotic properties in ApoE/ mice and increases plaque stability, by reducing plaque
macrophage content, without effects on collagen. Using the descending aorta of chow-fed ApoE/ mice, before significant
atherosclerotic plaque develops, we gained insight to early events in atherosclerosis. Interestingly, perivascular adipose tissue
(PVAT) and adventitial infiltration with macrophages and T-cells precedes atherosclerotic plaque or the impairment of
endothelium-dependent NO bioavailability (a measure of endothelial function). AVE0991 inhibited perivascular inflammation, by
reducing chemokine expression in PVAT and through direct actions on monocytes/macrophages inhibiting their activation,
characterized by production of IL-1β, TNF-α, CCL2 and CXCL10, and differentiation to M1 phenotype. Pretreatment with
AVE0991 inhibited migration of THP-1 monocytes towards supernatants of activated adipocytes (SW872). Mas receptors were
expressed in PVAT and in THP-1 cells in vitro, and the anti-inflammatory effects of AVE0991 were partly Mas dependent.
CONCLUSIONS AND IMPLICATIONS
The selective Mas receptor agonist AVE0991 exhibited anti-atherosclerotic and anti-inflammatory actions, affecting
monocyte/macrophage differentiation and recruitment to the perivascular space during early stages of atherosclerosis in
ApoE/ mice.
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This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles
in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/
10.1111/bcp.v82.4/issuetoc
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Introduction
Immune activation and inflammation are known to modu-
late the development of atherosclerotic plaques (Libby et al.,
2011; Weber and Noels, 2011; Back and Hansson, 2015) and
to regulate plaque stability (Chen et al., 2013). Recent studies
suggest that, in very advanced atherosclerotic plaques, ter-
tiary lymphoid structures are formed in the adventitia and
in perivascular tissues and may play modulatory, potentially
protective role (Hu et al., 2015). In contrast, the importance
of perivascular immune cell infiltration at earlier stages of
the development of atherosclerotic plaques may suggest a
pro-atherosclerotic role (Galkina et al., 2006; Clement et al.,
2015), although immune and inflammatory events at very
early stages of the disease, during the process of initiation
andmaintenance of plaque formation remain poorly defined.
Although much experimental evidence supports the role
of the immune system of atherosclerosis, this has not been
adequately translated into therapeutic strategies in humans
(Libby et al., 2011;Weber and Noels, 2011; Back and Hansson,
2015). This is mainly caused by the view that systemic immu-
nosuppression would be unacceptable for prevention and
treatment of cardiovascular diseases. A limited number of
clinical approaches are now being studied, including
systemic methotrexate or more recently, anti-cytokine
(anti-IL-1β or anti-TNF-α) treatments (Ridker and Luscher,
2014). These are based on evidence of high concentrations
of these cytokines in advanced plaques and their role as
checkpoints in atherosclerosis formation in vivo and in vitro.
Surprisingly, while seminal studies have characterized vascu-
lar inflammation in fully formed atherosclerotic plaques
(Galkina et al., 2006; Macritchie et al., 2012; Clement et al.,
2015; Hu et al., 2015), development of vascular inflammation
at early stages of atherosclerosis is less clear. Increased
oxidative stress and endothelial vascular dysfunction are
thought to be key events preceding atherosclerosis develop-
ment in humans (Guzik et al., 2000; Heitzer et al., 2001) and
in animal models (Laursen et al., 2001). In the present study,
we aimed to characterize immune cell infiltration in the vas-
cular wall and perivascular tissue at early stages of spontane-
ous atherosclerosis development in apolipoprotein E
(ApoE)/ mice, and focused on possibilities for pharmaco-
logical modulation of this process.
We also tested the possibility that pharmacological inhibi-
tion of such early inflammation would translate into protec-
tion from atherosclerosis and into increased plaque stability.
We focused on a strategy concomitantly known to modulate
inflammation and vascular responses, such as activation of
angiotensin 1–7 (Ang-(1–7)) receptors, as this could provide
a viable alternative for anti-inflammatory interventions in
atherosclerosis, as well as other vascular diseases, without
concerns associated with significant systemic immunosup-
pression (Passos-Silva et al., 2013; Magalhaes et al., 2015).
The peptide Ang-(1–7) exerts numerous protective effects
in the vascular system, including vasodilatory (Ren et al.,
2002), antioxidant (Raffai et al., 2011) and anti-inflammatory
effects (Lee et al., 2015). In endothelial cells, it stimulated en-
dothelial NOS (eNOS) and NO production (Sampaio et al.,
2006), as well as inhibiting vascular NADPH oxidase expres-
sion and activity (Benter et al., 2008). Thus, a combination
of such vasoprotective and anti-inflammatory properties
can make Ang-(1–7) and its mimetics particularly beneficial
in immune-mediated vascular disease, such as atherosclero-
sis. Indeed, 4 week infusion of Ang-(1–7) peptide, inhibited
development of atherosclerosis and protected against endo-
thelial dysfunction in ApoE/ mice (Tesanovic et al.,
2010). The majority of the protective, vascular and immune
effects of Ang-(1–7) are mediated through activation of the
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Mas receptor, and this action has been well characterized in
numerous tissues including brain, lung, vasculature and liver
(Sampaio et al., 2006). Ang-(1–7) Mas receptors are present on
immune cells and modulate decreased cytokine production
and activation of macrophages, T-cells and dendritic cells
(Capettini et al., 2012; Oliveira-Lima et al., 2015). Currently,
there is only one selective Mas receptor agonist, AVE0991,
which lacks significant affinity for angiotensin AT2 receptors
and is a non-peptide compound (Bosnyak et al., 2011). Our
preliminary studies have demonstrated anti-atherosclerotic
properties of AVE0991 through agonist activity at Mas recep-
tors (Jawien et al., 2012a,b). These effects are independent of
alterations in cholesterol metabolism, as AVE0991 does not
lead to any alteration of lipid profile (Jawien et al., 2012a).
The mechanisms of the potential anti-atherosclerotic effects
of AVE0991 are not known.
Accordingly, in the present study, we have assessed the ef-
ficacy of the selective Mas receptor agonist, AVE0991, to pro-
vide protection from atherosclerosis through preventing
early vascular and perivascular inflammation. To address
mechanisms, we used in vivo studies of ApoE/ mice, fed a
normal chow, as well as in vitro cultures of vascular and
inflammatory cells. We demonstrated that AVE0991 had
significant anti-atherosclerotic properties in ApoE/ mice,
and reduced plaque macrophage content. Using the descend-
ing aorta of chow-fed ApoE/ mice, before significant
atherosclerotic plaque develops, we gained insight into the
early events in atherosclerosis. Interestingly, perivascular
inflammation and infiltration of macrophages and T-cells
preceded atherosclerotic plaque development and the
impairment of endothelium dependent, NO-mediated
vasodilatations. AVE0991 inhibited vascular inflammation,
through reduction of chemokine expression in perivascular
adipose tissue (PVAT), and through direct actions on
monocytes/macrophages inhibiting their activation and
polarization towards the M1 phenotype. Thus, through
in vivo and in vitro studies, we demonstrated that the
Ang-(1–7) mimetic AVE0991 exhibited anti-inflammatory
properties affecting monocyte/macrophage differentiation
and recruitment to perivascular space at early stages of
atherosclerosis in ApoE/ mice.
Methods
Animals and treatment
All animal care and experimental procedures were approved
by the Jagiellonian University Ethical Committee on Animal
Experiments (no. 102/2012). Animal studies are reported in
compliance with the ARRIVE guidelines (Kilkenny et al.,
2010; McGrath & Lilley, 2015).Seventy eight female
C57BL/6JBomTac mice and 104 female ApoE-/- mice
(B6.129P2-Apoe<tm1Unc> N11) on the C57BL/6J
background were obtained from Taconic (Ejby, Denmark).
Mice were maintained on 12 h dark/12 h light cycles in air
conditioned rooms (22.5 ± 0.5°C, 50 ± 5% humidity) and ac-
cess to diet and water ad libitum. At the age of 12 weeks, mice
were randomly assigned into four groups receiving chow di-
ets, pre-mixed with placebo or with AVE0991, to deliver a
dose of 0.58 μmol·kg1 per day, for the following
1–3 months (Supporting Information Figure 1A). All diets
were prepared by Ssniff (Soest, Germany). Group one
consisted of C57BL/6J mice fed chow/placebo diet contain-
ing placebo, Group two – received chow/AVE0991. Group
three consisted of ApoE/ mice receiving chow/placebo
diet while group four were the ApoE/ mice fed
chow/AVE0991. Food intake was closely monitored and
did not differ between groups. After killing with CO2
inhalation, mice were perfused through the vasculature
with saline, and the thoracic and abdominal aorta was
carefully dissected.
Analysis of leukocytes in adipose tissue (AT)
and peripheral blood
The PVAT from the thoracic and abdominal aorta was iso-
lated as described by Mikolajczyk et al., (2016). Epididymal
fat pads were used as representative of visceral fat. ATs were
digested using collagenase type XI (125 U·cm3), collagenase
type IS (450 U·cm3) and hyaluronidase IV-S (60 U·cm3) in
PBS with calcium and magnesium for 20 min at 37°C, with
regular agitation and mashed through a 70 μm strainer
(BD Biosciences, USA) to yield single-cell suspensions
(Mikolajczyk et al., 2016). Cells were stained in FACS buffer
for 20 min at 4°C in the dark with the monoclonal
antibodies shown in Table S3 (Supporting Information
Table S3). Viability staining using BD HorizonTM Fixable
Viability Stain 510 (FVS510) showed 90 ± 3% cell viability
following isolation from PVAT and the staining procedure.
For analysis of peripheral blood monocytes, 1 mL of blood
was obtained by cardiac puncture and total peripheral
blood mononuclear cells were isolated by density gradient
as described (Mikolajczyk et al., 2016). Cells were analysed
by a FACSVerse flow cytometer (BD Biosciences, USA),
and data were analysed using Flow Jo v.10 (Ashland, OR,
USA). For each experiment, fluorescence-minus-one con-
trols (FMO) were performed. In selected experiments,
FMO gating strategies were confirmed by isotype controls.
The gating strategy is described in Supporting Information
Figure 1B.
Vascular reactivity measurements
Aortic segments from the thoracic part of the descending
aorta, 2 mm above the diaphragm, were mounted in
organ baths (Multi Wire Myograph System – 620 M; DMT
– Denmark), containing Krebs–Henseleit solution (composi-
tion: NaCl 118 mM, KCl 4.7 mM, KH2PO4 1.2 mM, MgSO4
1.2 mM, CaCl2 2.5 mM, NaHCO3 25 mM, glucose 11.7 mM)
and aerated with carbogen (95% O2/5% CO2) to reach pH
7.4, at 37°C and isometric tension studies were performed as
described before (Guzik et al., 2000, 2007a; Vinh et al., 2010;
Mikolajczyk et al., 2016). Arterial segments were stretched to
1.5 g and pre-contracted with PGF2α (average concentration
3μM) to obtain 70% of maximal KCl contraction).
Concentration–response relaxation curves to ACh (109 to
106 M) were obtained. After washout and 20 min equilibra-
tion period, rings were contracted with PGF2α (using the same
concentrations as above) and concentration–response curves
to sodium nitroprusside (SNP: 109 to 105 M) were
determined.
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Measurement of mRNA expression
Total RNA was obtained from cells using RNeasy Mini Kit
(Qiagen). RNA from AT was obtained using RNeasy Lipid Tis-
sue Mini Kit (Qiagen). Total RNA was measured by Nanodrop
2000 (Thermo Fisher Scientific). Reverse transcription of 1 μg
RNA was performed using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). mRNA expression of
chosen genes in PVAT were analysed using TaqMan® probes
(Thermo Fisher Scientific) (Supporting Information Table S1)
and TaqMan® Real-Time PCRMaster Mix (Thermo Fisher Sci-
entific) Reactionswere prepared and run on384-well plates on
the QuantStudio™ 7 Flex Real-Time PCR System or Applied
Biosystems® 7500 Real-Time PCR with standard protocol. Ex-
pressions of mRNA for some genes were analysed using
Fast SYBR® Green Master Mix (Thermo Fisher Scientific)
and primers from a table (Eurofins) (Supporting Information
Table S2). Calculations were made using QuantStudio™
Real-Time PCR Software or SDS Software 2.4 Data were
normalized to levels of GAPDH mRNA for SYBR® Green and
S18 for TaqMan®, and relative quantification was calculated
as 2ΔΔCt.
Atherosclerotic plaque quantification
The heart and ascending aorta were embedded in Tissue-Tek®
O.C.T. Compound (Sakura® Finetek, Japan) and snap-frozen.
Sections (10 μm thick) were collected at 100 μm intervals
starting from the appearance of the aortic valves. Sections
were air dried and fixed in 4% paraformaldehyde followed
by staining with Meyer’s haematoxylin and Oil Red O
(Sigma-Aldrich, USA). Stained sections were examined under
Olympus BX50 microscope (Olympus, Tokyo, Japan). For
each animal, total area of the lesion was measured as a mean
from four sections. To evaluate atherosclerotic plaque in
whole aorta, en-face technique was used. Aortas were fixed
in 4% formaldehyde, opened longitudinally, pinned onto
black wax plates and stained with Oil Red O (Sigma-Aldrich,
St. Louis, MO, USA). Images of the aorta were recorded using
a Nikon D3100 digital camera. Aortic lesion area and total
aortic area were calculated using ImageJ software as described
(Jawien et al., 2012a). Three sections from each mouse were
reviewed and scored without knowledge of the treatments
(blinding).
Immunohistochemical analysis
Aortic sinus sections were used for CD68 and α-smooth
muscle actin (α-SMA) detection by immunofluorescence
(Jawien et al., 2012a). Sections were air dried and fixed in ace-
tone, rehydrated with PBS before incubation in serum-free
Protein Block (DakoCytomation, Milan, Italy). Sections were
stained with rat anti-mouse anti-CD68 antibody (1:50;
AbSerotec, Oxford, UK) diluted in 1% blocking reagent
(Perkin Elmer, Cambridge, UK) and 0.3% Triton X-100 in
PBS overnight before being washed in TNT wash buffer
(Tris-HCl; pH 7.5; 0.15 M NaCl; and 0.05% Tween 20,
Sigma-Aldrich). Monoclonal anti–α-SMA FITC conjugated
(1:100, clone 1A4, Sigma-Aldrich) was added for 1 h before
washing. Sections were incubated with 1:200 Texas Red-
donkey anti-rat IgG (Jackson ImmunoResearch Laboratories,
Soham, UK) for 30 min. VECTASHIELD HardSet Antifade
Mounting Medium (Vector Laboratories) was used to stain
nuclei. Sections incubated without primary antibody were
used as a negative control. Images were recorded using fluo-
rescence microscope (Axio Observer Z.1, Zeiss, Germany)
with the ZEN software (Zeiss, Germany). Analyses were car-
ried out using Image J software. Three sections from each
mouse were reviewed and scored without knowledge of the
treatments (blinding).
Picrosirius red staining
To quantify collagen within the lesions of the aortic sinus,
serial cross sections (8 μm) were cut through the aorta begin-
ning at the origin of the aortic valve leaflets and stained with
Picrosirius Red. Serial formalin-fixed sections were incubated
for 2 h in a freshly prepared 0.1% solution of Sirius Red F3B
(Sigma-Aldrich) in saturated aqueous picric acid. After rinsing
twice in 0.01 M HCl and distilled water, sections were
dehydrated and mounted in Permount (Vector Laboratories).
Picrosirius Red staining was analysed by polarization micros-
copy and calculated using Image J without knowledge of the
treatments (blinding).
THP-1 cell culture and macrophage
differentiation
THP-1 monocytes (American Type Culture Collection,
Manassas, VA) were grown at 37°C in a 5% CO2 atmosphere
in RPMI 1640 supplemented with 10% FBS, 50 U·cm3
penicillin, and 50 U·cm3 streptomycin (pen/strep). Cells
were starved in 1% FBS RPMI 1640 (pen/strep) medium
overnight. AVE0991 (1 μM) was added 18 h before
stimulation. The Mas receptor antagonist A799 (5 μM) was
added 30 min before AVE0991. TNF-α (10 ng cm3) was
added for a 6 h incubation. To obtain differentiation into
macrophages, THP-1 cells were treated with 100 nM PMA
for 48 h at 37°C, and medium was replaced with RPMI
1640 10% FCS for another 24 h.
THP-1 macrophage polarization and effect of
AVE0991
After overnight starving (1% FBS RPMI 1640, pen/strep) rest-
ing macrophages (M0) were cultured for 24 h in the presence
of 20 ng·cm3 IFN-γ (PeproTech EC, UK) and 10 ng·cm3 LPS
to obtain M1 macrophages. M0 THP-1 macrophages were
parallel stimulated with AVE0991 (1 μM) 1 h prior adding
IFN-γ and LPS for 24 h. The phenotype of macrophages
were confirmed by gene expression of markers such as
CCR7, and CXCL10 for M1, whereas CD206 and CD209 were
used for M2.
SW872 cell culture and adipocyte
differentiation
SW872 cells were grown at 37°C in a 5% CO2 atmosphere in
DMEM supplemented with 10% FBS, 50 U·mL1 penicillin,
and 50 U·mL1 streptomycin. For SW872 differentiation to
adipocytes, medium was replaced with 10% FBS DMEM
with insulin (1 μM), dexamethasone (0.25 μM) and 3-isobutyl
1-methylxanthine (IBMX; 0.5 mM) for 48 h. Medium was
replaced with 10% FBS DMEM with insulin (1 μM) for
another 48 h. For the next 4 days, medium was replaced
with 10% FBS DMEM. A day before stimulation, cells were
starved in 1% FBS DMEM. For stimulation, AVE0991
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(1 μM) was added 18 h before stimulation with TNF-α
(10 ng·mL1) for 24 h. Supernatants were collected after
1000 x g centrifugation for 5 min and stored at 80°C
until chemotaxis assay.
Chemotaxis assay
For TNF-α stimulations, THP-1 cells were starved in 1%FBS
RPMI 1640 medium (with pen/strep) overnight. AVE0991
were added to THP-1 cell culture 18 h before TNF-α
(10 ng·cm3), 6 h stimulation. THP-1 cells were centrifuged
for 5 min at 400 x g and suspended in DMEM 1%FBS with
pen/strep and 1 × 106 cells were added to 8 μm pore
Transwell® 6 well Inserts (Corning®, US). Supernatants were
added to the bottom part and left for 4 h at 37°C in a 5% CO2.
Cells from bottom part were collected and counted by flow
cytometry (LSRII, BD). Fold change of chemotactic properties
were calculated comparing cell number passing through the
pores to the THP-1 cells stimulated with TNF-α and
passing through to supernatant from SW872 cells, without
stimulation.
Data and statistical analysis
The data and statistical analysis in this study comply with
the recommendations on experimental design and analysis
in pharmacology (Curtis et al., 2015). For comparison of
three or more independent groups, one-way ANOVA was
used with a Student–Newman–Keuls post hoc test. For com-
parison of two groups, unpaired two-tailed t-tests were
used. For comparison of the effects of AVE0991 on parame-
ters in different groups of mice, we employed two-way
ANOVA with a Bonferroni post hoc test. For comparisons of
vascular function in organ chamber experiments, repeated
measures ANOVA was used. P values <0.05 were considered
significant.
Materials
AVE0991 was a kind gift from Sanofi-Aventis (Frankfurt,
Germany); A799 was from Bachem (Bubendorf,
Switzerland); IFN-γ and TNF-α were supplied by PeproTech
EC (London, UK); insulin was from Cell Applications (San
Diego, CA) and PGF2α was supplied by Cayman Chemical
Company (Ann Arbor, MI). Sigma-Aldrich (St Louis, MO)
supplied ACh, LPS (from Escherichia coli 0111:B4;), dexa-
methasone, IBMX and SNP.
Results
AVE0991 reduces macrophage infiltration and
atherosclerotic plaque in ApoE/ mice
ApoE/ mice developed spontaneous plaque formation in
both aortic sinus and in the remaining segments of aorta (in
en-face preparations). At the 24th week of age on chow diet,
plaque was most evident in the aortic arch and sinus, with
the descending aorta exhibiting moderate plaque formation
(Figure 1A and B).
Oral administration (in the diet) of the Ang-(1–7)
mimetic, AVE0991, resulted in a significant reduction of
spontaneous atherosclerosis development, demonstrated by
Oil-Red-O staining in both aortic sinus and in en-face
preparations of the aortic arch and descending aorta at
24 weeks of age in ApoE/ mice. In the aortic sinus, this
protective effect was associated with dramatic reduction of
macrophage content (Figure 1C), while smooth muscle cell
and collagen content remained unaltered (Figure 1C and D),
indicating significant anti-inflammatory effect. This may be
an important indicator of increased plaque stability after
AVE0991 treatment.
Early atherosclerosis is associated with
significant perivascular leukocyte infiltration
in ApoE/ mice
To study early vascular events during the development of ath-
erosclerotic plaques, we focused on the descending aorta of
16, 20 and 24-week-old ApoE/ mice on chow diet. We
found that the total lesion, assessed by Oil-Red-O staining,
was still low at 24 weeks of age (Figure 1A). At this stage,
a moderate degree of impairment of endothelium depen-
dent NO-bioavailability in ApoE/ mice was present
(characterized by a shift in EC50 of relaxation to ACh),
while at 16 weeks, no such features of dysfunction were
observed (Supporting Information Fig. S2A and B). Inter-
estingly, we also did not find differences in the leukocyte
infiltration into the wall of the descending aorta, mea-
sured using flow cytometry to detect CD45+ cells, at ei-
ther 16 or 24 weeks of age in ApoE/ mice, compared
with C57BL/6J controls (Supporting Information Fig.
S2C). On the contrary, significantly increased leukocyte
infiltration was detected, using this method, in the PVAT
of ApoE/ mice at 16 and 24 weeks of age, indicating
that PVAT inflammation is an early feature of atheroscle-
rotic vascular dysfunction (Supporting Information Fig.
S2D). Importantly, such increased leukocyte infiltration
was specifically observed in the PVAT of ApoE/ mice,
but not in typical visceral (epididymal) AT (Figure 2A
and B).
AVE0991 inhibits perivascular leukocyte
infiltration in atherosclerosis
Next, we investigated the effects of oral treatment with
AVE0991 on the PVAT leukocytes (as CD45+ cells).
AVE0991 in the diet inhibited the PVAT content of CD45+
leukocytes, in 16, 20 and 24-week-old ApoE/ mice
(Figure 2A). In contrast, no effect was observed on leuko-
cyte content in wild type mice (Figure 2A) or in epididymal
visceral fat in either WT or ApoE/ mice (Figure 2B and
D) indicating specificity for inflammation in PVAT. Detailed
analysis of leukocyte content revealed that the Ang-(1–7)
mimetic had the most effect on the reduction of macro-
phages, T-cells and and natural killer (NK) cells in the
PVAT, but not in epididymal visceral fat (Figures 2C–D
and 3A–D). Importantly these inhibitory effects were
most evident at 16 weeks of age in the ApoE/ mice
(Figure 3). The PVAT from ApoE/ and C57BL/6J mice
show similar gene expression for the Mas receptor
(Supporting Information Table S4). Mas receptors are also
expressed in the human monocyte cell line (THP-1)
(Supporting Information Table S4), indicating that moncytes
can constitute an important target for AVE0991.
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AVE0991 inhibits chemokine and cytokine
expression in PVAT in ApoE/ mice
One of the key mechanisms for reduced macrophage and
T-cell perivascular infiltration in ApoE/ mice may
result from alteration of chemokines and adhesion mole-
cules in the PVAT. Expression of key chemokines previ-
ously linked to atherosclerosis, including CCL2 and
CXCL10 as well as CCL5, was significantly attenuated
Figure 1
AVE0991 decreases atherosclerotic plaque development and macrophage infiltration, but not collagen content in plaques from ApoE/ mice.
(A) Oil Red O–stained ‘en face’ preparation of aortas (scale bar = 1 cm, n = 5), and (B) Aortic sinus sections stained with Oil-Red-O obtained from
24-week-old ApoE/ and ApoE/ treated with AVE0991 (0.58 μmol·kg1 day1) (scale bar = 300 μm, n = 5). (C) Effect of 3 months AVE0991
treatment on plaque smooth muscle cell and macrophage content. Results are expressed as percentage of total plaque cells positive for α-SMA
(green) or CD68 (red) (bar = 500 μm) (n = 5). (D) Collagen staining of aortic root sections. Sections were stained using Picrosirius Red stain
and visualized under polarized light, (bar = 500 μm, n = 5); Bars represent means ± SEM; *P < 0.05, significantly different from ApoE/.
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by AVE0991 treatment, in the PVAT of ApoE/ mice,
while no change was seen in the aortic wall itself
(Table 1). This was associated with decreased expression
of the adhesion molecule, ICAM-1, in both PVAT and
aorta (Table 1), which in concert with changes in
chemokine expression may provide a mechanism for de-
creased recruitment of immune cells in early atherosclero-
sis. Importantly, key PVAT cytokines such as TNF-α and
IL-6 were also significantly attenuated in AVE0991-treated
ApoE/ mice (Table 1).
Figure 2
AVE0991 decreases leukocyte infiltration in PVAT, but not visceral AT in ApoE/mice at 16, 20 and 24 weeks of age. (A) Flow cytometric analysis
of total CD45+ leukocytes in the vascular stromal fraction isolated from PVAT of ApoE/ and C57BL/6J mice treated with placebo or AVE0991.
Representative examples are shown (above) and (below) as means ± SEM (n = 12 each group). (B) Representative flow cytometric analysis of leu-
kocytes in vascular stromal fraction isolated from visceral fat (VAT). Absolute number of CD45+ total leukocyte content in VAT compartment are
expressed as means ± SEM (n = 12 each). (C) Pie-charts describing % composition of subpopulations of leukocytes infiltrating PVAT and in (D),
leukocytes in VAT, from 24-week-old ApoE/ mice fed placebo and after treatment with AVE0991. Leukocyte subpopulations were identified
as described in Methods. ¶ P < 0.05, significantly different from C57BL/6J mice; * P < 0.05, significant effects of AVE0991.
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AVE0991 affects macrophage polarization in
PVAT in early atherosclerosis
ApoE/ mice were characterized by increased M1 macro-
phage content in PVAT as observed by flow cytometric
determination of CD206 and CD11c surface expression
on macrophages (Figure 4A). AVE0991 reduced the M1
macrophage population in ApoE/ mice while having
no effect on M2 macrophage content (Figure 4A). In order
Figure 3
AVE0991 treatment decreases macrophage, NK cell, T-cell and dendritic cell infiltration into PVAT in ApoE/mice. Representative flow cytomet-
ric analysis (24 weeks old) and average values of major leukocyte subpopulations in vascular stromal fraction isolated from PVAT of ApoE/ and
ApoE/ mice treated with AVE0991, aged 16, 20 and 24 weeks. Data shown are means ± SEM. Graphs show the effects of AVE0991 treatment
on content of (A) F4/80 + CD11b + macrophages (n = 12), (B) NK1.1+ NK cells (n = 6), (C) CD19+ B cells (n-10), (D) CD3+ T-cells (n = 12), (E)
CD11c+ I-Ab + dendritic cells (n = 6), and (F) Gr-1+ granulocytes (n = 6) in PVAT. * P < 0.05, significant effects of AVE0991.
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to further evaluate direct effects of AVE0991 on macro-
phage polarization, we used THP-1 cells in culture during
in vitro differentiation to M1 macrophages following stim-
ulation with LPS and IFN-γ, as described in the Methods
section (Figure 4B). This confirmed that AVE0991
inhibited the expression of mRNA for M1 markers
(CXCL10 and CCR7) during differentiation (Figure 4C).
Importantly this effect on M1 differentiation was reversed
by incubation with the Mas receptor antagonist A779 be-
fore exposure to AVE0991(Figure 4C).
AVE0991 affects peripheral blood monocyte
subsets
In vivo administration of AVE0991 resulted in a shift in
peripheral blood monocyte subsets as determined by
Ly6C and CD43 marker expression. In particular, content of
Ly6C++Cd43+ pro-inflammatory monocytes were reduced
(Figure 4D).
AVE0991 inhibits monocyte/macrophage
pro-inflammatory activation in vitro
To further investigate the anti-inflammatory mechanisms of
AVE0991, we studied the effects of 1 μM AVE0991 on TNF-α
stimulated phenotypic changes of THP-1 monocytes in cul-
ture. We observed that AVE0991-inhibited TNF-α induced
THP-1 cell activation characterized by increased expression
of mNA for IL-1β, CCL2 and CXCL10 (Figure 5A). These
changes were partly reversed by the Mas receptor antagonist
A779 (Figure 5A).
AVE0991 inhibits monocyte chemotaxis to
adipocytes in vitro
To address the effects of AVE0991 on monocyte chemotaxis,
we performed a chemotaxis assay using Boyden chambers to
assess the effects of AVE0991 treatment on chemotaxis of
TNF-α activated THP-1 cells towards SW872 adipocyte super-
natants (in the bottom chamber). These studies showed that
pretreatment of THP-1 cells with AVE0991 resulted in a
significant reduction of chemotaxis towards the supernatants
of both native and TNF-α activated SW872 human adipocytes
(Figure 5B). Pretreatment of SW872 cells with AVE0991 re-
sulted in similar inhibition of chemotaxis, but no additive ef-
fect was observed.
AVE0991 alters chemokine expression in
human adipocytes in culture
To investigate the effects of AVE0991 on adipocytes, we used
cultures of TNF-α stimulated SW872 human adipocytes.
These experiments showed that AVE0991 inhibited expres-
sion of mRNA for CCL2, CCL5, and IL-6 (Figure 5C). Similar
experiments, performed in human fibroblasts and VSMCs,
did not show significant effects of AVE0991 (Supporting In-
formation Figure S3), indicating that adipocytes and immune
cells constitute primary targets for anti-inflammatory actions
of AVE0991.
Discussion
While it is widely accepted that atherosclerosis is an immune
mediated disease (Ait-Oufella et al., 2011; Ketelhuth and
Hansson, 2016; Libby et al., 2011; Ridker and Luscher, 2014;
Weber and Noels, 2011), none of the clinically accepted phar-
macological treatments directly target the development of
vascular inflammation in atherosclerosis (Matusik et al.,
2012). Most of our knowledge regarding inflammation and
immunity in cardiovascular disease is derived from studies
of advanced atherosclerotic plaques, and little is known re-
garding the early stages of inflammation in atherosclerosis.
Accordingly, in the present study, using ApoE-/- mice fed nor-
mal chow, we have found that the increased leukocyte infil-
tration in the perivascular tissue was greater than that in the
vessel wall, measured by flow cytometry. Risk factors for ath-
erosclerosis such as hypertension, hyperlipidemia or diabetes
are known to promote perivascular inflammation (Galkina
et al., 2006; Galkina and Ley, 2009; Guzik et al., 2013; Guzik
et al., 2007b; Sagan et al., 2012; Vu et al., 2014). The renin-
Table 1
Effects of AVE0991 on expression of mRNA for selected pro-inflammatory cytokines, chemokines adhesion molecule in PVAT and aorta from
ApoE/ mice.
Aorta PVAT
Gene
Fold change after
AVE0991 treatment P value
Fold change
after AVE0991 treatment P value
IL6 0.84 0.37 0.30 <0.05
TNF-α 0.68 0.26 0.53 <0.05
CXCL10 0.81 0.33 0.24 <0.01
CCL2 0.52 0.22 0.38 <0.01
CCL5 0.88 0.42 0.65 <0.05
CXCR3 0.96 0.59 0.73 0.10
ICAM-1 0.76 <0.05 0.60 <0.05
The mRNA levels of key cytokines known to play a role in atherogenesis and chemotaxis were analysed from PVAT and aorta from 24 weeks of age
ApoE/ mice and ApoE/ mice treated with AVE0991 for 3 months. Results are shown as a fold change of mRNA expression from ApoE/ mice
after AVE0991 treatment to ApoE/ mice itself. mRNA abundance was measured by quantitative real-time PCR corrected for the mean S18 mRNA
expression. (n = 6 per group)
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angiotensin-system (RAS), and in particular angiotensin II, is
key in increasing perivascular recruitment of leukocytes
(Guzik et al., 2007a; Mikolajczyk et al., 2016), acting through
an increase of chemokine expression in the PVAT. CCL5 or
CCL2 are increased in early atherosclerosis (Podolec et al.,
2016). The RAS exerts its pro-atherosclerotic effects also
through T cell, B cell and monocyte/macrophage activation
(Hoch et al., 2009; Kirabo et al., 2014). We postulated that
stimulation of the alternative axis within the RAS, related to
Ang-(1-7) signalling, could provide a counter-regulatory,
anti-inflammatory effect in early atherosclerosis (Tesanovic
et al., 2010). Both inflammatory cells as well as perivascular
adipocytes and fibroblasts express Mas receptors for
Ang-(1-7) (Rubio-Ruiz et al., 2014; Simoes e Silva et al.,
2013). Mas receptor expression was higher in PVAT than
in other areas of aorta and it was not significantly increased
in ApoE-/- mice, in contrast to reports of the mouse penis
(Fraga-Silva et al., 2013),
Taking all these results into consideration, we used orally
active, selective Mas receptor agonist AVE0991 to stimulate
the Ang-(1-7) protective axis in ApoE-/- mice, and studied
its effects on atherosclerosis and vascular inflammation.
We found significant anti-atherosclerotic properties in
ApoE-/- mice (Jawien et al., 2012a) and extended these
Figure 4
AVE0991 decreases M1 but not M2 macrophage content in PVAT in ApoE/ mice and decreases M1 type differentiation of THP-1 monocytes
in vitro. (A) Flow cytometric analysis of M1/M2 macrophage polarization in PVAT isolated from C57BL/6J mice, C57BL/6J mice treated with
AVE0991, ApoE/ mice, and ApoE/ mice treated with AVE0991 at 24 weeks of age. Effect of AVE0991 treatment on macrophages M1
and M2 content in PVAT expressed as cells per mg of tissue (mean ± SEM; n = 6 each); ¶ P < 0.05, significantly different from C57BL/6 J; *
P < 0.05, significant effects of AVE0991. (B) Expression of mRNA marker genes for M1 macrophages (CCR7, CXCL10) and M2 macrophages
(CD206, CD209) in cell culture of THP-1 cells stimulated by LPS (10 ng·mL-1) and IFN-γ (20 ng·mL-1) for 24 h. * P < 0.05, significantly different
from M0. (C) Effect of AVE0991 (1 μM) treatment on M1 marker gene (CXCL10 and CCR7) mRNA expression after M0 macrophage polarization
to M1 macrophages. A779 (5 μM) was used to study the role of Mas receptors in this process (n = 7); P < 0.05, significant effects of AVE0991.
(D) AVE0991 decreases Ly6C++CD43+ monocytes in ApoE/ mice. Monocyte subpopulations (Ly6C++CD43+, Ly6C++CD43++, Ly6C +-
CD43++) in PBMC of 24-week-old C57BL/6J and ApoE/ mice upon treatment with AVE0991; ¶ P < 0.05, versus C57BL/6J; * P < 0.05, signif-
icant effects of AVE0991; (n = 6 per group).
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observations to show that AVE0991 affects atherosclerosis
development at early stages of plaque formation, in the de-
scending aorta in young ApoE-/- mice. In advanced plaques,
we also showed that AVE0991 reduced plaque macrophages,
without changing collagen content, thus beneficially
affecting plaque stability. This is in line with observations
that AVE0991 can affect co-stimulatory molecules
expression on CD11c+ cells in mouse spleen in atherosclero-
sis (Jawien et al., 2012a). To assess the anti-inflammatory ef-
fects of AVE0991 during the early stages of atherosclerosis,
Figure 5
Effect of AVE0991 on TNF-α activated THP-1 cytokine and chemokine mRNA expression, chemotaxis towards human adipocytes and chemokine
expression in human adipocytes. (A) Expression of selected pro-inflammatory mRNA cytokines and chemokines in THP-1 cells stimulated with
TNF-α (10 ng·mL-1) in presence of AVE0991 (1 μM) and/or the Mas receptor antagonist A779 (5 μM) (n = 6). (B) Chemotactic properties of
THP-1 cells stimulated with TNF-α to supernatants from SW872 adipocyte cultures, stimulated with TNF-α in absence or presence of AVE0991
(1 μM). Cell chemotaxis was analysed and expressed as a fold change of the number of cells passing through 8 μm pores under different condi-
tions, compared with THP-1 cells stimulated with TNF-α (10 ng mL-1) and with supernatants from native SW872 adipocytes without additional
treatment. Before testing chemotaxis, the THP-1 cells were stimulated for 6 h with TNF-α or stimulated with TNF-α for 6 h and then incubated with
AVE0991 (1 μM) for 18 h (n = 5). (C) Expression of pro-inflammatory CCL2, CCL5 and IL6 mRNA in SW872 cells differentiated to adipocytes and
stimulated with TNF-α (10 ng cm3) or saline (CTRL), with or without AVE0991 (1 μM) (n = 6); * P< 0.05, significantly different as indicated; t- test.
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we focused on characterization of vascular and perivascular
immune cells between the 16th and the 24th week of age in
chow-fed ApoE-/- mice. At week 16, plaques begin to develop
in the descending aorta but they constitute <3% of its total
surface (Elhage et al., 2004) and no significant NO-dependent
endothelial dysfunction is detected at this stage (Bonthu
et al., 1997; Fransen et al., 2008; Jawien et al., 2004).We found
that endothelial dysfunction appeared in the 24th week, at a
time when the plaque burden in the descending aorta starts
to exceed 4-5% of the total surface. This is important, as en-
dothelial dysfunction is considered to underlie atherosclero-
sis development in ApoE-/- mice (Laursen et al., 2001). In
the present study, we observed that in the absence ofWestern
diet, PVAT or adventitial inflammation and infiltration with
macrophages and T cells precedes not only significant athero-
sclerotic plaque development, but also the impairment of
endothelium-dependent NO bioavailability. Importantly, a
similar leukocyte increase was not observed in a typical
visceral fat tissue (epididymal AT). The composition of the
leukocyte subpopulations in PVAT was similar to reports in
advanced atherosclerosis (Galkina et al., 2006) and in hyper-
tension (Guzik et al., 2007a; Mikolajczyk et al., 2016). Inter-
estingly the main difference in PVAT infiltration between
these two conditions is in relative macrophage and T cell con-
tent (macrophages predominate in atherosclerosis while T
cells predominate in hypertension). AVE0991 reduced
perivascular infiltration of macrophages, T cells and NK cells
while infiltration of B cells, granulocytes and dendritic cells
was unaffected. Mas receptors have been identified on major-
ity of immune cells including macrophages, dendritic cells,
T cells and Mas receptor deficiency exacerbates systemic in-
flammation (Oliveira-Lima et al., 2015). Lack of effect of
AVE0991 on PVAT leukocyte infiltration in the control group
may also indicate differentmechanisms being involved in the
regulation of leukocyte accumulation in control and athero-
sclerotic conditions. Ang-(1-7) and the synthetic Mas recep-
tor agonist AVE 0991 have been effective in a number of
inflammatory models, such as arthritis (da Silveira et al.,
2010), asthmatic lung inflammation (Rodrigues-Machado
et al., 2013) and renal inflammation (Silveira et al., 2013).
The mechanisms of the anti-atherosclerotic effect of
AVE0991 was related to the reduction of chemokine (CCL2,
CCL5, CXCL10) expression in PVAT, as well as through direct
actions on monocytes/macrophages, inhibiting their activa-
tion, characterized by IL-1β, TNF-α, CCL2 and CXCL10, and
differentiation to the M1 phenotype. AVE0991 inhibited
migration of THP-1 monocytes towards supernatants of
activated adipocytes (SW872). Thus, through in vivo and
in vitro studies, we have demonstrated that the Mas receptor
agonist AVE0991 exhibits anti-inflammatory properties
affecting monocyte/macrophage differentiation and recruit-
ment to the perivascular space at early stages of atherosclero-
sis in ApoE-/- mice.
Our demonstration of the Mas receptor-dependent inhi-
bition of M1 macrophage differentiation by AVE0991 may
extend the potential usefulness of this compound to a num-
ber of conditions in which M1 macrophages play a key role
(Hammer et al., 2016). This includes pulmonary remodelling,
inflammation and right ventricular hypertrophy inmodels of
allergic asthma (Rodrigues-Machado et al., 2013), as well as its
protective effects in stroke (Lee et al., 2015) or liver cirrhosis
(Klein et al., 2015). Mechanisms of the vasoprotective effects
of AVE0991 include inhibition of oxidative stress (Ma et al.,
2016), stimulation of eNOS activation and NO production
(Pawlik et al., 2016). It also exerts effects in the CNS, decreas-
ing sympathetic outflow and renal effects leading to changes
in the renal proteome, in trems of antioxidant enzymes, apo-
ptosis regulators, inflammatory factors and metabolic en-
zymes (Suski et al., 2013). AVE0991 also inhibits
p22phox(Jawien et al., 2012a) and Nox2 and Nox4 NADPH
oxidases (Ma et al., 2016) and thus can change the pro- and
anti-oxidant balance, indirectly affecting vascular inflamma-
tion (Guzik et al., 2005).
While immune cell infiltration has been shown in
fully developed human and mouse atherosclerotic plaques
(Aubry et al., 2004), using flow cytometry, we did not detect
significant numbers of leukocytes in aortic intima andmedia,
in 16-24 week old ApoE-/- mice. This finding could indicate a
re-distribution of immune cells in the vessel during develop-
ment of atherosclerosis (Chalmers et al., 2015). Importantly,
the overall numbers of leukocytes detected in the aortic
intima and media are 5-fold lower than those in the adventi-
tia and in PVAT. This adventitial and periadventitial immune
cell presence remains throughout the course of atherosclero-
sis (Galkina et al., 2006; Galkina and Ley, 2009). Depending
on the stage of atherosclerosis, accumulations of these cells,
consisting predominantly of T cells and B cells and to a lesser
extent of other immune cells like dendritic cells or macro-
phages, termed tertiary lymphoid organs, may be pro- or
anti-atherogenic (Clement et al., 2015; Hu et al., 2015;
Srikakulapu et al., 2016). While the majority of studies
looking at perivascular leukocyte infiltration in atherosclero-
sis have focused on adventitia, inflammation in the PVAT is
evident from the earliest stages. The mechanisms linking
PVAT inflammation to atherosclerosis may be diverse and
may include chemotactic migration of PVAT immune cells
into adventitia and plaques, with release of cytokines which
can alter vascular function (Mikolajczyk et al., 2016). Inflam-
mation may also alter release of adipokines and adipocyte de-
rived relaxing factor from adipocytes (Antonopoulos et al.,
2015; Woodward et al., 2016). All of these mechanisms can
initiate and propagate plaque formation and plaque-specific
inflammation (Libby et al., 2011; Weber et al., 2011; Back
and Hansson, 2015).
It is important to note that, in our studies, femalemice were
used. This is a classical model in which immuno-pathogenesis
of atherosclerosis has been described (Caligiuri et al., 1999),
but both the RAS and inflammation differ betweenmale and fe-
male mice, including higher renal Ang-(1-7) concentration
(Zimmerman et al., 2015). Interestingly, we did not find (by
mass spectrometry) differences between the wild-type (C57BL/
6J) and ApoE-/- mice in Ang-(1-7), angiotensin-1-9 and angio-
tensin II levels in PVAT (data not shown).
Our study does not allow for unequivocal explanation of
the receptor-mediated mechanisms. While several studies
shown high selectivity of AVE0991 towards Mas receptors
(Santos et al., 2003), in selected conditions, effects could beme-
diated partly through angiotensin AT1 or AT2 receptors
(Tesanovic et al., 2010; Bosnyak et al., 2011). Partial reversal of
anti-inflammatory mechanisms by the Mas antagonist A779,
in our in vitro studies, indicates a need for further studies using
a combination of Mas receptor and AT2 receptor blockade.
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In summary, our results may provide a key mechanism for
the early anti-atherosclerotic effects of AVE0991. This
also suggests that AVE0991 could provide a valuable
alternative to typical immunosuppressants in vascular
disease as it acts simultaneously on the vasculature and on
immune/inflammatory cells. Such treatment could be more
widely accepted by the cardiovascular community while its
effects on immune and inflammatory mechanisms of athero-
sclerosis are clear.
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Table S1 List of TaqMan® probes.
Table S2 List of human primers used for SybrGreen qPCR.
Table S3 Flow cytometry antibodies used.
Table S4 Mas receptor mRNA expression in PVAT WT and
ApoE-/- (n=6-10), in aorta and PVAT from ApoE-/- (n=6) and
upon THP-1 cell activation (n=5).
Figure S1 (A) Experimental design and AVE0991 adminis-
tration. Fifty four 12 weeks of age C57BL/6J female mice
and fifty 12 weeks of age ApoE-/- mice were put on chow
diet. To observe effect of the Mas1 receptor agonist,
AVE0991 (0.58μmol kg-1 body weight day-1; Sanofi-Aventis,
Germany) was added to food (Soest, Germany) and twenty
four C57BL/6J female mice and fifty four ApoE-/- mice were
feed. To observe progress of atherosclerosis and inflamma-
tory state development, mice were killed at 16, 20 and 24
weeks of age. (B) Flow cytometric gating strategy.
Leukocytes were gated by CD45 staining. From leukocytes,
further sub-populations of B cells (CD19+), dendritic cells
(CD11c+I-Ab+), granulocytes (Ly6c+Ly6g+), macrophages
(F4/80+CD11b+), natural killer (NK) cells (NK1.1+) and T-cells
(CD3+) were identified. To demonstrate different states of
macrophage polarization, we set up gates forM0macrophages
(defined as CD206-CD11c-), M1macrophages (CD206-CD11c
+) and M2macrophages (CD206+CD11c-).
Figure S2 At early stage of atherosclerosis in ApoE-/- mice
there is no impairment of endothelium-dependent NO bio-
availability and visible inflammation in aorta whereas in-
crease of inflammatory cells infiltration is evident in
perivascular adipose tissue. (A, in C57BL/6J and ApoE-/- mice
at (A) 16 weeks and (B) 24 weeks of age (n=5) (C, D) Represen-
tative flow cytometric analysis of leukocytes infiltration to
(C) aorta and (D) periaortic adipose tissue in C57BL/6J and
ApoE-/- mice at 24 weeks of age. Leukocytes infiltration was
calculated as a cell number per mg of tissue. *P<0.05 by T test.
Figure S3 Effect of AVE0991 on TNF-α activated human vas-
cular smooth muscle cells (HVSMC) cytokine and chemokine
mRNA expression. Expression of selected proinflammatory
mRNA cytokines and chemokines in HVSM cells stimulated
with TNF-α (10ng cm-3) in presence of AVE0991 (1μM)
and/or Mas receptor antagonist A779 (5μM) (n=5). *P<0.05
vs CTRL (control) by T test.
AVE0991 is anti-inflammatory in atherosclerosis BJP
British Journal of Pharmacology (2017) 174 4055–4069 4069
